Genomic studies of hematologic malignancies have identified a spectrum of recurrent
somatic alterations that contribute to acute myeloid leukemia initiation and maintenance …

Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …

Isocitrate dehydrogenases (IDHs) are enzymes involved in multiple metabolic and
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …

Mutations in IDH2 genes (m IDH2) occur in approximately 12% of patients with acute
myeloid leukemia. Enasidenib is an oral, small-molecule inhibitor of mIDH2 proteins …

The success of all-trans retinoic acid (ATRA) therapy for acute promyelocytic leukemia (APL)
provides a rationale for using retinoic acid (RA)-based therapy for other subtypes of acute …

Epigenetic modifications affect gene expression without changes in the actual DNA
sequence. Two of the most important mechanisms include DNA methylation and histone tail …

Mutations in the isocitrate dehydrogenase gene (IDH1) were recently described in patients
with acute myeloid leukemia (AML). To investigate their prognostic significance we …

Although there has been significant progress in acute myeloid leukemia (AML) treatment in
younger adults during the last decade, standard induction therapy still fails to induce …

Introduction The chromosomal rearrangements of the mixed-lineage leukemia gene MLL
(KMT2A) have been extensively characterized as a potent oncogenic driver in leukemia. For …

Mutations in the nicotinamide adenine dinucleotide phosphate+–dependent isocitrate
dehydrogenase gene 2 (IDH2) have recently been found in patients with acute myeloid …